Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  BUDAPEST STOCK EXCHANGE  >  Richter Gedeon Vegyeszeti Gyar Nyrt    GDRB   HU0000123096

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( HUF)
Sales 2017 442 B
EBIT 2017 69 098 M
Net income 2017 62 184 M
Finance 2017 83 808 M
Yield 2017 1,47%
Sales 2018 468 B
EBIT 2018 76 514 M
Net income 2018 75 372 M
Finance 2018 123 B
Yield 2018 1,93%
P/E ratio 2017 20,24
P/E ratio 2018 16,69
EV / Sales2017 2,65x
EV / Sales2018 2,42x
Capitalization 1 255 B
More Financials
Company
The Chemical Works of Gedeon Richter Plc develops and manufactures pharmaceuticals.It operates through the following segments: Pharmaceuticals, Wholesale and Retail, and Others.The Pharmaceutical segment comprises of the research and development, manufacture, retail and marketing of pharmaceutical... 
Sector
Pharmaceuticals
Calendar
02/05Earnings Release
More about the company
Surperformance© ratings of Richter Gedeon Vegyeszeti
Trading Rating : Investor Rating :
More Ratings
Latest news on RICHTER GEDEON VEGYESZETI
01/15 Drugmaker Dermapharm gears up for likely first German IPO of 2018
2017 RICHTER GEDEON VEGYESZETI GYAR : Allergan and Gedeon Richter set to expand use o..
2017 RICHTER GEDEON VEGYESZETI GYAR : Allergan and Gedeon Richter ready to knock on F..
2017 RICHTER GEDEON VEGYESZETI GYAR : Allergan and Richter Announce Positive Topline ..
2017 RICHTER GEDEON VEGYESZETI GYAR : Extraordinary Announcement
2017 RICHTER GEDEON VEGYESZETI GYAR : Extraordinary Announcement
2017 RICHTER GEDEON VEGYESZETI GYAR : Extraordinary announcement
2017 RICHTER GEDEON VEGYESZETI GYAR : announces the acquisition of a minority equity ..
2017 RICHTER GEDEON VEGYESZETI GYAR : signed a licensing agreement with Pharmanest to..
2017 RICHTER GEDEON VEGYESZETI GYAR : Extraordinary announcement
More news
Sector news : Generic Pharmaceuticals
01/15 Drugmaker Dermapharm gears up for likely first German IPO of 2018
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/12 ASTRAZENECA : Receives FDA Approval for Breast Cancer Treatment
01/12 WPP Buys London-based Mash Strategy
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 7 571  HUF
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Gábor Orbán Chief Executive Officer
Erik Bogsch Executive Chairman
Attila Chikán Chairman-Supervisory Board
Gábor Gulácsi Chief Financial Officer & Director
Istvan Greiner Director-Research